Press Releases Filter Filter Results Year 2024 (4) 2023 (5) 2022 (23) 2021 (17) 2020 (38) 2019 (36) 2018 (23) 2017 (25) 2016 (20) 2015 (25) 2014 (26) 2013 (31) 2012 (35) July 11, 2019 Abiomed First Quarter Fiscal 2020 Earnings and Conference Call Notification June 13, 2019 Impella Featured as an Innovative Technology at U.S. Capitol Event Showcasing Improvements to Women’s Health May 29, 2019 Abiomed to Present at Upcoming Investor Conferences May 21, 2019 FDA Confirms Impella RP is Safe and Effective; Only Right-Sided Device with FDA Approval May 21, 2019 National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery May 16, 2019 Impella SmartAssist Platform Launches at SCAI, Designed to Further Improve Patient Outcomes May 13, 2019 FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy May 2, 2019 FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial May 2, 2019 Abiomed Announced Q4 FY 2019 Revenue of $207 Million and 31.6% Operating Margin April 23, 2019 Clinical Data Highlights Advantages of Protected PCI to Enable Complete Revascularization and Improved Patient Quality of Life April 11, 2019 Abiomed Fourth Quarter Fiscal 2019 Earnings and Conference Call Notification April 4, 2019 Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval March 18, 2019 Impella RP Post-Approval Study Data Presented at ACC 2019 March 14, 2019 Benefits of Heart Recovery with Impella Showcased at ACC 2019 February 20, 2019 $100 Million Invested in Clinical Research for Impella … 7 8 9 10 …
